Ranchi News Desk

New Service Launched at Creative Biolabs: Bispecific TCR Generation Service to Unleash Full Potential of TCR Therapy

 Breaking News
  • No posts were found

New Service Launched at Creative Biolabs: Bispecific TCR Generation Service to Unleash Full Potential of TCR Therapy

August 02
04:30 2022
With an industry-leading portfolio of services and regulatory expertise, Creative Biolabs has unveiled one-stop bispecific TCR design and construction services to advance tumor treatment research.

New York, USA – As the first bispecific T-cell receptor (TCR) cell therapy, Kimmtrak, was approved by the United States Food and Drug Administration (FDA) in March 2022, for unresectable or metastatic uveal melanoma, this new research direction presents a bright prospect and great potential, attracting global scientists to explore it in depth.

Delving into the CRO service on bispecific antibody (BsAb) development for decades, Creative Biolabs now announces bispecific TCR design and construction services. With optimized workflows to help drive success across clients’ specific programs and priorities, the team holds the competence of advancing clients’ projects at a fast turnaround with ensured outcomes.

The expert team is capable of designing classic bispecific TCR with engineered TCR targeting tumor cells and functional scFv targeting T cell marker. The previous cases of bispecific TCR design of fusing a humanized anti-CD3 single chain antibody fragment to an affinity-matured T-cell receptor that recognizes target HLA-presented peptides have laid the foundation for future custom projects.

“We fully understand and appreciate this innovative strategy, and have explored the whole mechanism of it. Firstly, bispecific TCR molecules recognize and bind to cancer cells exhibiting a defined target. Then, the free end of the Bispecific TCR molecule redirects circulating T cells to the tumor site. The Bispecific TCR generates a bridge between the T cell and the cancer cell. Finally, lytic granules are released, killing cancer cells,” as introduced by a scientist at Creative Biolabs, “we will consider every step during the process to make sure a potential molecule is engineered efficiently with positive results.”

The service package of bispecific fusion protein generation also covers bispecific antibody-HSA fusion protein generation for the engineering of various BsAbs including scFv-HSA-scFv, scDiabody-HSA, and tandem scFv-HSA, as well as bispecific antibody-toxin fusion protein generation, such as tandem scFv-toxin.

More information can be found at https://www.creative-biolabs.com/BsAb.

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs has been dedicated to offering services on antibody discovery, engineering, production, and analysis. Especially, the bispecific antibody (BsAb) team has gathered a collective of experienced scientists committed to providing high-quality services to customers all over the world, covering BsAb design, purification, engineering, manufacturing, and BsAb analysis service. Besides, a variety of standard or customized BsAb products are also available for different research applications.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/BsAb

Related Articles